Browse Articles
Discover research articles across all indexed journals
OCTOPUS: A retrospective, multicenter study of real-world cabozantinib treatment of patients with advanced renal cell carcinoma in France—Subgroup analyses of treatment sequences and optimization.
472 Background: Cabozantinib is an established therapy for advanced renal cell carcinoma (aRCC) in France. We evaluated real-world data from the OCTOPUS study to assess treatment sequences and explore strategies for therapeutic optimization. Methods: OCTOPUS was a real-world, retrospective, non-comparative, non-interventional study of 252 patients receiving second-line (2L) cabozantinib therapy at 26 centers in France between 2018 and 2021 (NCT05444933). Exploratory analyses of treatment sequences and endpoints including duration of treatment (DoT), progression-free survival (PFS), overall survival (OS) and disease control rate (DCR) were performed for subgroups of patients based on cabozantinib dose modifications, local treatment (radiotherapy or surgery) and receipt of third-line (3L) treatment. Results: In total, 252 patients (median age, 63.0 years; lung metastases, 63%; bone metastases, 52%) were included; 61% had prior tyrosine kinase inhibitor (TKI) therapy, and 37% received prior immunotherapy (IO). Patients who underwent local treatment or cabozantinib dose modifications exhibited longer 2L DoT and PFS than those without these interventions (Table). In total, 157 patients (62%) received 3L therapy post cabozantinib (55% nivolumab, 26% TKI), and 14 patients were still on cabozantinib at study end. Dose modification rates were higher among patients who received 3L therapy (≥1 reduction, 67% vs 55%; ≥1 interruption, 69% vs 56%). Those receiving 3L therapy demonstrated improved outcomes (Table); the median OS from 2L cabozantinib initiation in patients who received 3L treatment was 20.5 months (95% CI, 18.0–22.6). Conclusions: Cabozantinib outcomes may be enhanced with dose modifications and local treatment. These strategies may delay the need for 3L therapy in patients with oligoprogressive disease, potentially improving long-term disease control. Clinical trial information: NCT05444933 . Subgroup N (%) Median (95% CI) DoT for 2L cabo, months Median (95% CI) PFS from 2L cabo start, months DCR for 2L cabo, % (n/n) Overall population 252 (100) 7.4 (6.1–8.5) 6.9 (5.7–8.2) 76.9 (160/208) Dose modificationsNoYes 58 (23)194 (77) 2.5 (1.6–3.5)8.6 (7.6–9.9) 3.5 (2.2–5.7)7.6 (6.5–8.7) 62.5 (20/32)79.5 (140/176) Local treatment a,b NoSurgery or focal treatment c Radiotherapy 153 (61)25 (10)52 (21) 6.0 (4.6–7.6)9.6 (4.4–15.0)9.3 (7.6–13.3) 6.2 (5.3–8.2)8.0 (4.4–9.5)7.2 (5.2–10.1) 78.0 (96/123)90.1 (20/22)78.3 (36/46) 3L treatmentNoYes 95 d (38)157 (62) 4.3 (3.2–6.9)8.2 (6.9–9.6) 5.1 (3.1–7.3)8.0 (6.2–9.1) 69.7 (46/66)80.3 (114/142) a Patients may receive surgery and radiotherapy; b 41 patients had a surgery not related to aRCC; c Only surgeries or focal treatments related to aRCC are presented; d 14 patients were receiving 2L cabozantinib at study end.
Explore the possible influence of Sjogren’s syndrome on thyroid cancer: A literature data mining and meta-analysis
Objectives To explore the potential influence of Sjogren’s syndrome (SS) on thyroid cancer (TC). Methods First, a literature data mining (LDM) approach was used to reconstruct functional pathways connecting SS and TC. A meta-analysis was then performed to examine the expression changes of genes mediated by SS using 16 TC case/control expression datasets, with results validated through the TCGA/GTEx dataset. Finally, gene set enrichment analysis (GSEA) and survival analysis using GEPIA2 were conducted on the significant genes. Results Our findings indicate that SS may increase the risk of TC by activating 14 TC promoters (PDCD1, NTRK1, LGALS3, CD274, FOXP3, BCL2, CYP1A1, HMGB1, TGFB1, CCL2, PLA2G7, TFF3, LCN2, and CLDN1) and suppressing three TC inhibitors (MIR145, MIR30C1, and EP300). Four molecules (PLA2G7, TFF3, LCN2, and CLDN1) exhibited significant expression changes in TC patients (LFC > 1 or < -1; p < 2.07E-04), which were confirmed in TCGA/GTEx expression analysis. These results highlight three possible mechanisms—the SS-PLA2G7-CCL2-TC pathway, the SS-LCN2-LGALS3-TC pathway, and the SS-CLDN1-BCL2-TC pathway—that may explain how SS contributes to TC development. Enrichment analysis suggests that SS may affect TC prognosis by regulating leukocytes and tolerance induction. Survival analysis indicates that SS may enhance TC survival through the regulation of the CLDN1 and EGF pathways. Conclusion LDM-based pathway analysis highlighted three genetic pathways through which SS may adversely affect TC progression, while SS may enhance TC survival via the CLDN1 and EGF pathways, highlighting the need for further research.
Efficacy of ossiculoplasty in patients with chronic otitis media with severe to profound hearing loss
Implementing Indiana regimen salvage high-dose chemotherapy in relapsed germ cell tumors in Slovakia.
642 Background: Salvage chemotherapy for relapsed testicular germ cell tumors (GCT) remains controversial, however, large retrospective series show higher cure rates with high-dose chemotherapy (HDCT) and peripheral blood stem cell transplant (PBSCT) compared to conventional dose chemotherapy (CDCT). Successful implementation of HDCT salvage treatment in high-volume centers is an important step towards achieving optimal cure rates in relapsed GCTs. Methods: 22 relapsed GCT patients were treated at National Cancer Institute in Slovakia with first (41%), second (54%) and third line (5%) salvage HDCT between 2014 and 2024. Median age at 1 st HDCT cycle was 33 years (range 21-55). Of the 22 patients, 3 (14%) had pure seminoma, 3 (14%) had primary mediastinal non-seminoma (PMNSGCT), 10 (45%) patients had cisplatin resistant disease, 7 (32%) and 15 (68%) of patients received 1 and 2 cycles of HDCT, respectively, 5 (23%) received maintenance oral etoposide and 6 (27%) had post-HDCT surgery. Indiana regimen consisted of 750mg/m2 etoposide and 700mg/m2 of carboplatin given on days -5,-4,-3 followed by PBSCT on day 0. Of 22 patients, 3 have received single dose CarboPEC (carboplatin, etoposide, cyclophosphamide) regimen in 2014 and 2015. Results: Median time between two cycles was 43 days (range 26-89) showing decreasing trend over the last years. 2-year PFS and OS were 40% (95% CI 0.19-0.61) and 34% (95% CI 0.13-0.55) and 5-year PFS and OS were 32% (95% CI 0.1-0.54) and 27% (0.06-0.48). Kaplan-Meier analysis produced inaccurate outcomes due to small sample size, currently 32% of patients is alive and disease-free. Predictors of unfavorable outcome were non-seminoma, NPMGCT, 1 cycle of HDCT, CarboPEC regimen and platinum resistant disease. Patients who underwent post-HDCT surgical resection had longer OS compared to patients unable to undergo surgery HR 4,85 (95% CI 1,69-13,9), p = 0.01 Patients receiving pre-HDCT bridging CDCT regimens had significantly worse OS compared to patients going directly to HDCT, HR 0 (95% CI 0-0), 5 year OS 19% vs 100%, p = 0.05. 10% of patients with cisplatin resistant disease is surviving beyond 5 years. There was one (4.5%) treatment-related death due to septic shock. Conclusions: HDCT is an effective salvage option in heavily pretreated relapsed GCTs. Our study suffers from weakness associated with small number of patients and selection biases. However, increasing expertise and timely delivery of HDCT results in cures in relapsed GCTs including cisplatin resistant subgroup.
Receipt of poly(ADP) ribose polymerase inhibitors (PARPi) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring <i>BRCA1/2</i> alterations.
108 Background: PARPi are approved for the treatment of pts with mCRPC either as single agents or as a combination with an androgen receptor pathway inhibitor (ARPI) [PMID: 37442702]. In a US Food and Drug Administration (FDA) pooled analysis, the benefit from PARPi appeared greatest for pts harboring BRCA1/2 alterations [PMID: 38484203]. However, real-world uptake of PARPi in pts with mCRPC with BRCA1/2 alterations is unknown. Herein, our objective was to assess the usage of PARPi in real-world pts with mCRPC harboring BRCA1/2 alterations. Methods: A de-identified nationwide Flatiron Health electronic health record (EHR)-derived database was used to extract pt-level data. Eligibility criteria: pts with mCRPC harboring alterations in BRCA1 or BRCA2 or both and alive after 8/15/2020 (i.e., 3 months following the approval of the first PARPi, rucaparib, in mCRPC) with available treatment information. The data cutoff date was 5/31/2024. Pts were categorized into two cohorts based on the receipt of any PARPi or not. Baseline characteristics at the time of mCRPC diagnosis, including age, race-ethnicity, and insurance plan, were collected in both cohorts. Results: Of the overall cohort of 24,105 pts with metastatic prostate cancer, 443 pts had mCRPC with BRCA1/2 alterations and were eligible and included in this analysis. 227 (51.2%) received a PARPi, while 216 did not (48.8%). Among the 227 pts who received a PARPi, 166 received it as a single agent (73.1%), 40 received it in combination with an ARPI (17.6%), and 21 received it in combination with other agents (9.3%). The median age was 72 in both cohorts (IQR 65 – 79 in patients receiving a PARPi and 66 – 78 in patients who did not). Other baseline characteristics in both groups are shown (Table). Conclusions: Despite PARPi demonstrating survival improvement in pts with mCRPC with BRCA1/2 alterations, a significant proportion of pts do not receive them. Our findings highlight the need to improve education among clinicians of level 1 evidence and improve access to life-prolonging therapies in pts with mCRPC. Baseline characteristics of pts with mCRPC who received vs. did not receive a PARPi. Characteristic Subgroup Pts who received a PARPiN = 227 Pts who did not receive a PARPiN = 216 Race-ethnicity, n (%) Asian 9 (4) 1 (0.5) Black 22 (9.7) 30 (13.9) Hispanic-Latino 10 (4.4) 10 (4.6) White 149 (65.6) 124 (57.4) Other and unknown 37 (16.3) 51 (23.6) Insurance, n (%) Commercial health plan 192 (84.5) 182 (84.3) Medicare-other government programs 31 (13.7) 18 (8.3) Medicaid 1 (0.4) 3 (1.4) Others and unknown 3 (1.3) 13 (6)
Concurrent pembrozulimab and radiation treatments in the management of locally advanced bladder cancer in cisplatin-ineligible patients.
817 Background: Pembrolizumab (P) is commonly used to treat cisplatin-ineligible patients with locally advanced bladder cancer. We previously reported a potential synergistic effect of concurrent radiation and immunotherapy, https://doi.org/10.1200JCO.2020.38.15_suppl.e17020. Here, we present our updated experience with this combination. Methods: After transurethral resection of bladder tumor (TURBT), patients received Pembrolizumab 200 mg IV every 3 weeks and radiation treatments, starting 1 week after Pembrolizumab initiation. A total of 64-65 Gy was delivered to the bladder and pelvis. Pembrolizumab was continued for 1 year. Response was assessed by follow-up cystoscopies and serial imaging studies. Results: Between October 2021 and May 2023, 14 patients with locally advanced bladder cancer (cT2-T4 or LN+ve) were treated. Median age was 74 years (range 62-91), with a male-to-female ratio of 9:5. ECOG performance status was 0-1 in 5 patients, 2 in 7 patients, and 3 in 2 patients. All patients completed radiation treatments, while 10 patients completed 1 year of Pembrolizumab, 3 patients completed 6-12 months, and 1 patient received less than 6 months. Follow-up cystoscopy was performed in 12 patients, with 7 (58.3%) showing a complete clinical response. Grade 3/4 immune-related adverse events (irAEs) occurred in 1 patient. At a median follow-up of 16 months (range 6-23 months), 9/14 patients (64.2%) remained without evidence of distant disease, 3/14 patients (21.4%) had oligometastatic disease treated with stereotactic body radiation therapy (SBRT) and are now without distant disease, and 2/14 patients (14.4%) developed multiple distant metastases. Conclusions: Concurrent radiation and immunotherapy is an effective option with a favorable side-effect profile for cisplatin-ineligible patients with locally advanced bladder cancer. Incorporating other non-chemotherapeutic agents, such as antibody-drug conjugates, into concurrent radiation-immunotherapy combinations warrants further investigation.
Cabozantinib in patients (pts) with non-locally pretreated brain metastases (BM) from renal cell carcinoma (RCC): Results of the multicenter CABRAMET phase II trial (NCT03967522).
533 Background: Despite dramatic progress in metastatic RCC treatments, pts with BM remain with poor outcome and were mostly excluded from clinical trials. Local treatments on BM are standard today. Methods: Adult pts with histologically proven RCC and BM ≥ 5 mm (or > 8 mm if solitary) including at least one non-locally pretreated, < 3 prior systemic treatments excluding cabozantinib, ECOG PS 0 or 1 and steroids < 40 mg/day were included. Primary endpoint was BM progression free survival rate at 6 months (6m-BM-PFS) according to modified RANO-BM criteria by central review. Secondary endpoints were BM response and response duration, extracranial response, PFS, overall survival and safety. 25 evaluable pts were required to evaluate the main endpoint. Results: 26 pts were included, 25 were evaluable for the primary endpoint and median follow up time was 39.8 months [5.9-49.7]. The 6m-BM-PFS was 56.0% [unilateral 95%CI 37.9-] (14/25 pts). BM response was partial response (PR) for 61.5% (16/26) pts and median duration of response was not reached, 66.7% pts being event-free 24 months after BM response. Extracranial response was PR for 38.5% (10/26). Median PFS was 8.1 months [95%CI 4-11.9], and median BM PFS 8.4 months [95%CI 5.4-NR]. Median overall survival was 15.8 months [95%CI 9.7-35.0]. No new safety signals were observed. Conclusions: This is the first prospective trial assessing cabozantinib in RCC pts with non-locally pretreated BM. These results confirm the efficacy of cabozantinib on BM previously reported in retrospective series. Clinical trial information: NCT03967522 . Pts characteristics. Pts number N = 26 Median age (years) [range] 67 [44-86] Gender: F / M, n 5 / 21 ECOG PS: 0 / 1,n 10 / 16 RCC: non-clear cell / clear cell, n 2 / 24 Prior nephrectomy : n 16 Number of BM: 1 / 2 / >3, n 9 / 7 / 10 Prior BM treatments: Overall/ Surgery/ Radiation, n 10 / 3 / 10 Prior systemic treatment: 0 / 1 / >2, n 7 / 15 / 4 IMDC: Favorable / Intermediate / Poor, n 7 / 10 / 9
Implementation research to develop an optimized delivery model for effective implementation of evidence-based interventions to reduce stillbirth in India: A study protocol
Background Stillbirth remains a public health concern in India, despite a decrease in reported rates. Inconsistent data collection hampers clear understanding the burden of stillbirth, and interventions for its reduction are scattered across various national programs. This research aims to explore effective strategies to improve the delivery and uptake of high-quality antenatal and intrapartum care services which have the potential to reduce stillbirth rates in various states of India. Methods This mixed-method, multi-site study in India will be conducted in three phases: Phase 1: Formative Phase; Phase 2: Development of a Comprehensive Package for Stillbirth Reduction and Optimization of the implementation model and Phase 3: Scale-up of comprehensive package and monitoring of optimized strategy/model. Participants will include pregnant women, women who have recently delivered, family members, respectable community members, healthcare workers and staff, state and district health authorities. The effectiveness of intervention package and optimized implementation model in reducing stillbirth will be evaluated using a pre-post quasi-experimental design. The burden of stillbirth will be estimated through community survey, recording pregnancy outcomes for women who have delivered within the past one year. Various methods including semi-structured questionnaires, verbal autopsies, and in-depth qualitative interview guides, review of clinical case sheets will be used to assess the causes of stillbirth. Additionally, government health facilities will be assessed and strengthened over study period. This study will utilize implementation science theories, models, and frameworks (TMF), including the Consolidated Framework for Implementation Research (CFIR) to identify barriers and facilitators, and the evaluative TMF of RE-AIM (Reach Effectiveness Adoption Implementation and maintenance) to monitor the optimized model. The primary outcome is the development of a scalable, sustainable model of intervention package and delivery strategies to reduce stillbirths. The secondary outcome includes a robust estimation of burden, timing, and risk factors of stillbirths across all study sites. Certain sites will conduct an economic evaluation to assess the incremental cost of implementing comprehensive packages using the optimized implementation model. Discussion This innovative study addresses a critical public health gap in context of stillbirth reduction in India. Integrating proven interventions with real-world implementation challenges across diverse regions, this project aims to develop a comprehensive and replicable model. If successful, this model can significantly improve stillbirth prevention in low-resource settings. Trial registration ClinicalTrials.gov CTRI-2024/07/069796.
A geospatial and statistical analysis of land surface temperature in response to land use land cover changes and urban heat island dynamics
Efficacy of systemic treatments for advanced non-clear cell renal cell carcinoma: A single-arm systematic review and meta-analysis.
550 Background: Non-clear cell renal cell carcinoma (nccRCC) represents a genetically and histologically diverse subset of renal cancers, accounting for 15–30% of all renal malignancies. Patients with nccRCC generally face poorer prognoses compared to those with clear cell renal cell carcinoma (ccRCC). While many therapies, such as tyrosine kinase inhibitors (TKI), mammalian target of rapamycin (mTOR) inhibitors, and immune checkpoint inhibitors (ICI), have broadened treatment options for nccRCC, high-quality randomized controlled trials (RCTs) assessing these treatments remain scarce. Consequently, RCT-based reviews provide an incomplete understanding of systemic therapy in nccRCC. In contrast, single-arm trials (SATs), more commonly conducted in nccRCC patients, offer additional insights into therapeutic efficacy. This study aims to synthesize evidence from both RCTs and SATs to comprehensively evaluate the efficacy of systemic treatments for nccRCC. Methods: We conducted a systematic review and meta-analysis of SATs and arms of RCTs, retrieving studies from PubMed, MEDLINE, EMBASE, and the Cochrane Library up to October 1, 2024. Primary outcome was objective response rate (ORR), and secondary outcomes were progression-free survival (PFS), and overall survival (OS). A random-effects meta-analysis was employed to pool data, and subgroup analyses were conducted based on treatment regimens. Results: Thirty-two studies encompassing 1,958 patients were included in the meta-analysis. The pooled ORR across all treatments and therapy lines for nccRCC was 20% (95% CI 15%–26%). The median PFS and OS were 5.56 months (95% CI 4.03–7.09 months) and 17.25 months (95% CI 12.48–22.01 months), respectively. Among them, the pooled ORR for TKI and ICI monotherapy was 19% (95% CI 10%–30%) and 19% (95% CI 13%–26%), respectively, while the pooled ORR for TKI and ICI combination therapy was 39% (95% CI 28%–51%). For first-line therapy, the ORR was 20% (95% CI 12%–28%). Combination therapies (e.g., TKI+ICI, TKI+mTOR and ICI+ICI) demonstrated a higher pooled ORR of 32% (95% CI 19%–46%), while monotherapies (TKI, mTOR or ICI) had an ORR of 14% (95% CI 8%–21%). In papillary RCC (pRCC), the ORR for first-line therapy was 17% (95% CI 9%–26%). Combination therapies showed an ORR of 31% (95% CI 14%–51%), and single-agent therapies had an ORR of 12% (95% CI 6%–21%). Conclusions: This meta-analysis provides evidence supporting the efficacy of existing systemic therapies, particularly combination therapies, in advanced nccRCC. However, the inherent limitations of single-arm analysis necessitate further large-scale, multicenter trials to validate these findings and guide future clinical practice.
A prospective provincial registry of PSMA PET CT for recurrent prostate cancer (PREP): Results for 4135 men.
35 Background: PREP was initiated in Ontario to provide access and characterize performance of PSMA PET CT among men with recurrent prostate cancer after primary definitive treatment (RP or RT). Methods: Between 03/18 and 09/22, 4135 men were accrued. Men were enrolled and imaged with 18F-DCFPyL at 1 of 6 participating sites within 1 of 6 clinical cohorts. Standardized reports delineated sites of recurrence and post PET management changes. Linkage to provincial databases allowed estimation of overall survival and utilization of salvage radiotherapy after PET. Results: Median follow-up was 1.8 years; key findings are in Table 1. Significant predictors of a positive PET scan on multi-variable analysis included: higher PSA at time of PET and clinical cohort (highest for cohort 4). Significant predictors of change in management were type of recurrence (highest for loco-regional) and higher PSA. Significant predictors of worse overall survival included clinical cohort (worst for cohort 4), extent and type of metastases (worst for mixed bone/lymph/visceral or extensive metastases). A change in management post PET was a significant predictor of improved survival. Conclusions: The PREP registry facilitated access to PSMA PET/CT with high rates of disease detection and impact on management. Significant factors associated with survival were extent and sites of disease detected and management change after PET. Clinical trial information: NCT03718260 . PREP registry: Key findings. Total (n=4135) Cohort 1 (n=255): BF within 3 months from RP and pN+ or PSA >0.1 Cohort 2 (n=1500): BF following RP Cohort 3 (n=1040): BF post RPand adjuvant or salvage RT Cohort 4 (n=263): BF while on salvage hormone therapy Cohort 5 (n=176): BF following Therapy for Oligo-metastases on prior PET Cohort 6 (n=901): BF following primary RT Median Age at scan (IQR) 71.0 (66.0–76.0) 66.0 (61.0–70.0) 70.0 (65.0–74.0) 72.0 (67.0–76.0) 74.0 (69.0–79.0) 73.0 (66.0–77.0) 75.0 (70.0–79.0) Median PSA (IQR) at scan (ng/mL) 1.3 (0.3–4.0) 0.7 (0.2–2.5) 0.3 (0.2–1.0) 1.1 (0.5–2.7) 3.5 (1.6–7.2) 2.4 (1.0–5.3) 4.4 (3.1–7.4) PET: Negative Findings 1216 (29.4) 84 - 88 (32.9 - 34.5)* 749 (49.9) 258 (24.8) 19 (7.2) 18 - 22 (10.2 - 12.5)* 84 (9.3) PET: Locoregional Recurrence 1377 (33.3) 95 (37.3) 471 (31.4) 295 (28.4) 63 (24.0) 34 (19.3) 419 (46.5) PET: Oligo-Metastatic (≤5 metastases) 1021 (24.7) 45 (17.6) 224 (14.9) 354 (34.0) 111 (42.2) 70 (39.8) 217 (24.1) PET: Extensive Metastases 521 (12.6) 29 (11.4) 56 (3.7) 133 (12.8) 70 (26.6) 52 (29.5) 181 (20.1) Change in management post PET 2070 (50.1) 135 (52.9) 585 (39.0) 552 (53.1) 152 (57.8) 99 (56.3) 547 (60.7) Radiotherapy within 6 months 1729 (41.8) 165 (64.7) 866 (57.7) 346 (33.3) 88 (33.5) 49 (27.8) 215 (23.9) Died during follow-up period 138 (3.3) 1 - 5 (0.4 - 2.0)* 18 (1.2) 30 (2.9) 35 (13.3) 8 -12 (4.5 - 6.8)* 44 (4.9) BF: Biochemical Failure; RP: Radical Prostatectomy; RT: Radiotherapy; IQR: Interquartile Range. *Small cell size.
Time from medication order to administration of cabazitaxel (C) vs. lutetium Lu-177 vipivotide tetraxetan (Lu) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
109 Background: C and Lu are associated with overall survival benefit and approved for pts with mCRPC after prior treatment with docetaxel and an androgen receptor pathway inhibitor (ARPI). However, in real-world settings, administering Lu requires coordination across specialties and resources [PMID: 36637862], which could delay its administration. Herein, we sought to compare the time from medication order to administering the first dose of C versus Lu. Methods: This study used pt level data from the nationwide Flatiron Health electronic health record (EHR)-derived de-identified database. Inclusion criteria: availability of the date of the first order of single-agent C or Lu and the date of first administration of the drugs. The time between the first medication order to the administration of single-agent C or Lu was measured. Wilcoxon rank-sum test was used to compare the median days between medication order to administration between these 2 agents and a stratified analysis by practice type and insurance was performed. Results: Of 2,329 orders, 2,045 orders were for C between 1/1/2013 and 1/26/2024, while 284 were for Lu between 8/1/2013 and 12/6/2023. The time from medication order to administration was significantly longer with Lu (median 22 days, IQR 12-43) compared to C (median 7 days, IQR 3-14, p < 0.001). Time from medication order to administration of C and Lu by practice type and insurance is summarized (Table). At the time of the first order, pts in Lu cohort, compared to C cohort, were significantly older (median age 74 vs. 72, p < 0.001), more likely to be treated at an academic practice (27% vs. 15%, p < 0.001), and more likely to be covered by a commercial health plan (80% vs. 73%, p < 0.001). Conclusions: Our results show that it takes significantly longer to administer Lu compared to C across different practice types and most insurance plans. These results could inform healthcare policies aimed at improving access to Lu and guide treatment selection in the clinic. Time from medication order to administration of C and Lu by practice type and insurance. Category Subtype (number of orders for C/number of orders for Lu) CN = 2045 LuN = 284 p-value Practice type, mean (range) (days) Academic (315/77) 1.3 (0 – 59) 9.2 (0 – 55) < 0.001 Community (1730/207) 13 (0 – 243) 44 (1 – 282) < 0.001 Insurance, mean (range) (days) Commercial (1494/226) 11 (0 – 163) 32 (0 – 215) < 0.001 Medicare/other government programs (266/46) 10 (0 – 120) 46 (0 – 282) < 0.001 Medicaid (32/2) 9 (0 – 76) 28 (0 – 55) 0.8 Others (72/6) 12 (0 – 42) 21 (0 – 41) 0.2 Unknown (181/4) 14 (0 – 243) 76 (39 – 91) < 0.001
Real-world discontinuation and efficacy data of abiraterone acetate/prednisone (AAP) plus androgen deprivation therapy and radiotherapy in localized prostate cancer.
367 Background: Data from STAMPEDE trial confirmed Overall survival benefit for patients with high-risk localized or locally advanced prostate cancer treated with Radiotherapy (RT) plus 24-month Abiraterone/prednisone (AAP) and ADT. Nevertheless, a 17% discontinuation rate in the experimental arm of the trial was reported. Here we present a cohort of patients treated with this regimen at two Institutions. Methods: We conducted a retrospective analysis of patients with localized or locally advanced prostate cancer who underwent treatment with AAP+ADT+RT with at least 18 months of follow-up. Primary endpoint was the discontinuation rate of AAP in the ITT population. Secondary endpoints included PSA decline rate, PSA nadir <0.02 ng/mL and safety. Clinical data were collected from patients’ electronic records. GraphPad Prism software was used for chart design, data comparison and statistical analysis. Results: Overall, 104 patients completed RT (60 Gy in 20#) and met inclusion criteria for this analysis. Of them, 61 (58.7%) patients had N0 disease, while 43 (41.3%) had N1 disease. AAP was discontinued prior the pre-planned two years in 29/104 (27.9%) patients. Among those who discontinued, median duration of AAP was 13.5 mo [3.2-23.5], while median duration of ADT was not reached [6.1-35.9]. Reasons for AAP discontinuation included hepatotoxicity (n=8), heart concerns and oedema (n=7 and 2, respectively), brain fog (n=2), hypokalaemia (n=2), quality of life deterioration (n=5), other (n=3). In total, 73/104 patients (70.2%) reached a PSA nadir <0.02 ng/mL at the 18-month analysis. No significant difference in achieving a PSA < 0.02 ng/mL was seen between those stopping AAP early (20/29 - 69%) and those who didn't (53/75 - 70.7%). Conclusions: Our analysis revealed a notably high rate of early discontinuation of AAP in the real-world setting in patients treated for their localized prostate cancer when compared to what observed in the STAMPEDE trial. Nonetheless, early discontinuation did not negatively impact on short-term treatment efficacy as a possible surrogate for long-term treatment benefit. Future studies on larger populations with longer follow-up are warranted to confirm these results.
Cost analysis of corneal tissue processing: A scoping review protocol
Introduction Diseases affecting the cornea are a group of pathological conditions responsible for the main causes of blindness worldwide. Corneal transplantation aims to replace dysfunctional corneal tissue with a transparent tissue graft obtained from a deceased donor, which enables the full recovery of lost vision. Processes are initially performed to prepare the corneal tissue for transplantation in order for this transplant to be viable. There is a gap in knowledge regarding the costs of these processes. This review aims to carry out a robust, broad and current mapping of studies which analyze the costs of processing corneal tissue for transplantation. Objective The objective of this study is to map the evidence produced in the literature on cost analysis studies of corneal tissue processing. Materials and methods A scoping review will be conducted to map the topic, gather different research designs and identify the available scientific evidence on corneal tissue processing. To this end, a scoping review protocol was developed, registered in the Open Science Framework (accessed at: DOI 10.17605/OSF.IO/2X89U), following the good practices described by the Joanna Briggs Institute. The review report will be guided by the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews checklist. The data will be presented descriptively, with a summary of the studies found. The guiding research question of the study is: What is the scope of scientific evidence on the cost analysis of corneal tissue processing for transplants?
Nutrients, bioactive compounds and antinutritional properties of marigold genotypes as promising functional food
Prognosis in metastatic renal cell cancer (mRCC) with major venous involvement (MVI): A population-based study.
454 Background: Limited data exist on outcomes in mRCC patients with major venous involvement (MVI). Assessment of impact of a given variable on prognosis in cancer patients is challenging given competing causes of death (PMID: 25417239). This analysis aims to estimate cancer prognosis in mRCC patients with MVI, considering death from competing causes. Methods: Data from the Surveillance Epidemiology and End Results (SEER) database (2010-2020) were analyzed for survival and mortality in mRCC patients with MVI. 5-year (y) overall survival (OS) and 5-y probability of cancer death were calculated using the actuarial method in SEER*Stat 8.4.4, reported as percentages with 95% confidence intervals (CI). Results were based on the site of MVI (renal vein, inferior vena cava [IVC]) and stratified by age (<65, >65 years), gender (male, female), and race/ethnicity (Non-Hispanic [NH] White, NH Black, NH Asian/Pacific Islander [API], Hispanic). Results: A total of 89047 mRCC patients were included in our analysis of whom 10785 (12%) had major venous involvement (MVI). Overall, patients who experienced MVI had worse prognosis as compared to those who did not have MVI (5-y OS: 53.2% vs 84.4% and 5-y cancer death: 38.6% vs 8.2% respectively). Among cohort with MVI, prognosis was poor with IVC involvement as compared to involvement of renal vein (5-y OS: 36% vs 57%; 5-y cancer death: 56% vs 35% respectively). Patients who had the worst prognosis with MVI included older adults (>65 y) (5-y OS: 47.8%; 5-y cancer death: 40.8%) and NH Black (5-y OS: 41.5%; 5-y cancer death: 49.8%) (Table). Conclusions: Prognosis in mRCC with MVI, especially with IVC involvement, was poor, particularly for older adults (>65 y) and NH Black patients. Further research is needed for better prognostication and risk stratification to improve outcomes for high-risk patients. Subgroup No MVI MVI N 5-year OS (%), 95% CI 5-year Cancer death (%), 95% CI N 5-year OS (%), 95% CI 5-year Cancer death (%), 95% CI Overall population 78,262 84.4 (84.1-84.7) 8.2 (8.0-8.4) 10,785 53.2 (52.0-54.3) 38.6 (37.5-39.7) Age <65 y 49,217 89.0 (88.6-89.2) 6.5 (6.3-6.8) 5,897 57.5 (56.0-59.0) 36.8 (35.4-38.3) >65 y 29,045 77.0 (76.1-77.2) 10.9 (10.5-11.4) 4,888 47.8 (46.0-49.5) 40.8 (39.2-42.4) Gender Male 49,221 83.0 (82.7-83.5) 8.9 (8.6-9.2) 7,503 53.2 (51.8-54.6) 38.3 (37.0-39.6) Female 29,041 86.5 (86.0-86.9) 7.0 (6.7-7.4) 3,282 53.0 (51.0-55.0) 39.4 (37.4-41.3) Race/ethnicity NH White 49,520 84.0 (83.7-84.4) 8.3 (8.0-8.5) 7,182 53.5 (52.1-54.8) 38.0 (36.7-39.3) NH Black 8,878 82.0 (81.0-82.9) 8.1 (7.5-8.8) 685 41.5 (37.1-45.9) 49.8 (45.4-54.1) NH API 4,747 86.0 (85.1-87.4) 8.5 (7.6-9.4) 713 52.9 (48.2-57.3) 39.9 (35.5-44.1) Hispanic (All Races) 13,826 86.5 (85.8-87.2) 7.9 (7.4-8.4) 2,014 56.2 (53.4-58.8) 36.7 (34.1-39.2) N: number of cases; OS: overall survival; CI: confidence interval; NH: Non-Hispanic; API: Asian/Pacific Islander; MVI: major venous involvement.
Interim analysis of the “shutter speed” MRI model to detect clinically significant prostate cancer.
339 Background: Prostate cancer (PCa) MRI can fail to identify high-grade lesions, and mis-grade lesions, up to 30% of the time. Objective imaging techniques are needed to better discern aggressive from indolent PCa. While the dynamic contrast enhanced (DCE) sequence of mpMRI has not played a routine role in identifying clinically significant PCa (csPCa), improvements in DCE may aid in the detection of cancers with weak signals on other MRI sequences. We studied the ability of “Shutter Speed” MRI (SSMRI), a technique based on DCE including objective measurements of perfusion, to detect csPCa lesions and adverse pathology. Methods: We analyzed PCa lesions from patients who underwent standardized MRI (Siemens VIDA 3T, endorectal coil; planned n=124) followed by radical prostatectomy with whole-mount histopathology (n=95). An experienced GU pathologist annotated lesion size and Grade Group (GG). An experienced radiologist reviewed all mpMRI lesions, and the SSDCE parameters were measured post-acquisition using a standardized software package. This paired data analysis compared the ability of SSMRI (SSDCE, T2, DWI) and mpMRI (standard DCE, T2, DWI) to detect csPCa lesions (ISUP ≥ GG 2, ≥5mm) or adverse pathology (extracapsular extension [ECE], seminal vesical invasion [SVI], lymph node invasion [LNI], GG≥4, or their composite [CO]) using logistic regression. We constructed receiver operator characteristic curves (ROC), and AUC was compared for the detection of csPCa (primary endpoint) and adverse pathology (secondary endpoint) (Table). Results: Patient mean age and PSA at diagnosis were 64.6 years and 9.7 ng/mL respectively. 91 lesions were assessed, of which 25 met criteria for csPCa. When comparing ROC for detection of csPCa, SSDCE improves the AUC of DCE alone from 0.72 (95% CI 0.50-0.95) to 0.83 (95% CI 0.71-0.95), and when added to mpMRI improves the AUC from 0.80 (95% CI 0.75-0.86) to 0.94 (95% CI 0.88-1.00) (p <0.0001). While the AUC improved by 0.13 for the detection of SVI when SSDCE was added to mpMRI, this did not reach statistical significance, nor did it for any other adverse feature. Conclusions: SSMRI significantly enhanced the detection of csPCa lesions. A larger cohort is needed to assess SSMRI’s ability to detect adverse pathology. These findings further the efforts toward earlier and more accurate diagnosis of csPCa. Comparison of AUC: Addition of SS to DCE and mpMRI. Methods and AUC (95%CI): DCE SSDCE mpMRI SSMRI P value csPCa 0.72 (0.50-0.95) 0.83 (0.71-0.95) 0.80 (0.75-0.86) 0.94 (0.88-1.00) P<0.0001 ECE 0.64 (0.50-0.79) 0.63 (0.48-0.78) 0.70 (0.59-0.81) 0.72 (0.59-0.86) P=0.66 SVI 0.75 (0.61-0.89) 0.75 (0.60-0.90) 0.71 (0.60-0.83) 0.84 (0.72-0.96) P=0.12 LNI 0.64 (0.48-0.79) 0.59 (0.42-0.76) 0.71 (0.62-0.81) 0.73 (0.57-0.88) P=0.88 GG≥ 8 0.67 (0.50-0.83) 0.63 (0.45-0.82) 0.67 (0.56-0.79) 0.74 (0.57-0.91) P=0.23 CO 0.66 (0.51-0.81) 0.62 (0.46-0.78) 0.70 (0.58-0.81) 0.71 (0.56-0.85) P=0.67
INTerpath-004: A phase 2, randomized, double-blind study of adjuvant pembrolizumab (pembro) with V940 (mRNA-4157) or placebo for renal cell carcinoma (RCC).
TPS610 Background: The PD-1 inhibitor pembro is approved as monotherapy for the adjuvant treatment of patients with RCC at increased risk of recurrence following nephrectomy or nephrectomy and resection of metastatic lesions based on results from the phase 3 KEYNOTE-564 trial. Novel combination strategies could provide further clinical benefit in the adjuvant setting. V940 (mRNA-4157) is an individualized neoantigen therapy hypothesized to work in synergy with immune checkpoint inhibitors by generating de novo tumor-specific T-cell activity. V940 + pembro showed improved clinical outcomes for stage III/IV melanoma compared with pembro alone in the phase 2b KEYNOTE-942 study. INTerpath-004 is a global, multicenter, randomized, double-blind, phase 2 trial (NCT06307431) designed to evaluate the efficacy and safety of adjuvant pembro + V940 or placebo in patients with RCC who have undergone nephrectomy. Methods: Eligible patients are adults with histologically or cytologically confirmed RCC with clear cell or papillary histology (intermediate-high risk [pT2 Gr4, N0, M0 or pT3 Gr3/4, N0, M0], high risk [pT4, N0, M0 or pT any stage, N1, M0], or M1 NED [solid, isolated, soft tissue metastases that can be completely resected at the time of nephrectomy or ≤2 years from nephrectomy]) with or without sarcomatoid features. Patients must have undergone nephrectomy and/or metastasectomy ≤12 weeks prior to randomization and be tumor-free as assessed by investigator. Patients must not have received prior systemic therapy ≤4 weeks or radiotherapy ≤2 weeks prior to randomization. Approximately 272 patients will be randomly assigned 1:1 to receive pembro 400 mg intravenously every 6 weeks for ≤9 cycles in combination with either V940 1 mg or placebo intramuscularly every 3 weeks for ≤9 doses or treatment discontinuation due to unacceptable toxicity, disease recurrence, patient withdrawal, or investigator decision. Randomization will be stratified by histology (clear cell vs papillary) and disease risk (intermediate-high vs high vs M1 NED). Imaging assessments (computed tomography or magnetic resonance imaging) will be performed every 12 weeks through year 2, every 16 weeks in years 3-5, and every 24 weeks in year 6 and beyond. The primary endpoint is disease-free survival by investigator assessment. Secondary endpoints include distant metastasis-free survival, overall survival, and safety parameters, including adverse events (AEs), laboratory test results, and vital signs. AEs will be monitored throughout the study and for 30 days after the last dose of treatment (90 days for serious AEs) and graded per National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. Efficacy will be assessed in all randomly assigned patients, and safety will be assessed in all patients who received ≥1 dose of study intervention. Recruitment is ongoing. Clinical trial information: NCT06307431 .
Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD).
20 Background: Clinical features of people with mHSPC may affect their outcomes from the addition of ARPIs to androgen deprivation therapy (ADT). The STOPCAP Collaboration is seeking IPD to reliably investigate potential ARPI effect modifiers and determine who benefits more from an ARPI vs docetaxel plus ADT doublet. Methods: Full methods are in registered protocols (CRD42023431331; CRD4202540066). We sought IPD for completed trials examining effects of ARPIs for mHSPC. Initially, we examined ARPI effects using intention-to-treat, two-stage, common-effect meta-analysis of hazard ratios (HRs), adjusted for a core set of covariates and use of concomitant docetaxel. Main effects were based on overall survival (OS). Interaction effects were based on progression-free survival (PFS) to maximise power, then OS whenever PFS interactions were found (P<0.10). Within clinically-relevant subgroups, ARPI and docetaxel doublet effects were compared using two-stage, contrast-based, random-effects network meta-analysis (NMA). Results: By October 2024, we had updated IPD from five trial comparisons: LATITUDE, STAMPEDE A vs G, SWOG-1216, ENZAMET, and STAMPEDE A vs J. Based on these (2882 events/5472 pts), adding an ARPI to ADT improved OS (HR=0.69, 95% CI=0.64-0.74). Four trial comparisons (excluding SWOG-1216) provided PFS data (2781 events/4161 pts) and showed improved PFS (HR=0.49, 95% CI=0.45-0.53). The relative benefit of ARPIs on PFS increased with younger age (interaction p=0.034), higher BMI (interaction p=0.048), and lower burden of metastases (interaction p=0.096). These effects were similar for OS (age interaction p=0.035; BMI interaction p=0.031; volume interaction p=0.25). The age effect was most pronounced in the abiraterone trials. Combining IPD from the ARPI + ADT and docetaxel + ADT trials (GETUG-AFU-15, CHAARTED, STAMPEDE A vs C) in NMA suggested that overall, an ARPI doublet may improve OS more than a docetaxel doublet (HR=0.85, 95% CI=0.70-1.03). However, when the NMA was confined to participants with high-volume, synchronous disease, where docetaxel is most efficacious (but excluding SWOG-1216, for which these data were not available), effects on OS were: HR=0.89, 95% CI=0.74-1.06. Conclusions: Our preliminary results suggest that people with mHSPC who are younger, have a higher BMI, or have low volume disease, may benefit more from ARPIs. ARPI and docetaxel doublets seem similarly effective in high-volume, synchronous disease. We will present updated analyses, incorporating recently received PEACE 1 IPD, for a clearer picture of ARPI effects, including subgroup-specific effects. Ongoing collection of IPD from other key trials will allow robust comparison of ARPI doublet with triplet therapy (including docetaxel), guiding more personalised treatment.
A multicenter cross-sectional survey of the role of community pharmacists, attitudes, and perceptions in preventing and controlling cardiovascular diseases
Background Cardiovascular diseases are a leading cause of mortality globally and impose suffering and economic difficulties, particularly in low- and middle-income countries. Community pharmacists present an opportunity for effective prevention and control of cardiovascular diseases. The overarching aim of the study was to evaluate factors associated with the extent of involvement, barriers and facilitators, and perceptions of Lesotho community pharmacists in preventing and controlling cardiovascular diseases. Methods The study utilised a quantitative cross-sectional survey. A semi-structured questionnaire was distributed to licensed community pharmacists across four districts between March and July 2023. Parametric and non-parametric tests were performed for data analysis using a Statistical Package for Social Sciences version 26. Results Apart from medicine dispensing, community pharmacists were mostly involved in hypertension (mean = 4.38±.73) and diabetes (mean = 4.17±.91) screening, weight management advice (mean = 3.81±.87), disease education (mean = 3.93±.83), medication management therapy (mean = 3.74±.99, 3.81±.88), referral of and follow up on patients (mean = 3.70±.98 and 3.87±.92). There was a significant association between the extent of involvement and pharmacy location, experience of community pharmacists, availability of tools, number of patients seen daily, and presence of other healthcare professionals at a community pharmacy (p<0.05). The most common barriers were related to patient factors (>75% agree to strongly agree), such as lack of awareness of community pharmacists’ services. Community pharmacists possessed positive (mean >3) attitudes and perceptions regarding their role in cardiovascular disease management. Conclusions Besides dispensing medicine, community pharmacists had varying extent of involvement in health promotion activities. The provision of these services differed between socio-demographic groups. Community pharmacists possessed good knowledge, positive attitudes towards their cardiovascular disease management role. Thus, they can improve cardiovascular disease outcomes. However, the barriers potentially limit their scope of practice and encourage inconsistent community pharmacy services. The findings present pertinent information to policy-makers, regulators, and pharmacists that can inform the development of frameworks to improve clinical and pharmacy practice in Lesotho and low- and middle-income countries.